1 year ago
India Develops Indigenous Multi-Stage Malaria Vaccine, AdFalciVax
Imagine a tiny bug called malaria that makes people very sick.
Scientists in India have created a new vaccine called AdFalciVax to fight this bug.
This vaccine is special because it attacks the bug at two different points in its life, unlike other vaccines.
It's shown good results in early tests, and could be better than existing vaccines.
It is easy to store and uses cheap ingredients, making it useful in hot places.
The vaccine is still being tested and may be ready in about seven years, helping to keep people from getting malaria and stopping it from spreading.
India develops indigenous multi-stage malaria vaccine candidate, AdFalciVax.
The vaccine targets two stages of the Plasmodium falciparum parasite.
Early testing shows promising results, potentially offering benefits over existing vaccines.
AdFalciVax remains stable for nine months at room temperature and uses cost-effective ingredients.
The vaccine is in the preclinical stage, with potential public use in approximately seven years.
- Who
- Developed by ICMR, RMRC Bhubaneswar, NIMR, and DBT-NII.
- What
- Development of AdFalciVax, an indigenous multi-stage malaria vaccine.
- Where
- Developed in India.
- When
- Currently in the preclinical stage; potential public use in approximately seven years.
- Why
- To combat the deadliest form of malaria with a more effective and accessible vaccine.
Key facts
- Vaccine Name
- AdFalciVax
- Target
- Plasmodium falciparum parasite
- Stages Targeted
- Two stages
- Stability
- Nine months at room temperature
- Adjuvant
- Alum
- Development Stage
- Preclinical
- Estimated Timeline
- Around seven years for public use
